SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing heightened volatility ahead of earnings, with the community polarized between those anticipating a major breakout fueled by aggressive short covering and others bracing for a post-earnings sell-off due to macroeconomic headwinds. While long-term investors are highlighting management's growth strategy and the new Notre Dame partnership, many traders remain deeply skeptical, expressing frustration over the stock's persistent range-bound performance and the potential for a negative market reaction regardless of fundamental strength.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending as investors weigh its dominant market position in AI data center cooling and power management against recent volatility and valuation concerns. While the company continues to see strong demand tailwinds and positive analyst sentiment ahead of its upcoming investor events, the stock is experiencing significant profit-taking after a rapid run-up.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to a contentious FDA advisory committee briefing document that challenges the statistical analysis plan (SAP) used in the HOPE-3 clinical trial, prompting investors to weigh intense regulatory scrutiny against the potential for a favorable panel vote. While the company maintains that the analysis was finalized appropriately and reflects real-world efficacy for DMD patients, the market remains highly volatile as traders react to conflicting interpretations of the trial data and the critical upcoming vote.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently the focal point of intense market volatility, as shares face a sharp pre-earnings sell-off while the community debates whether the decline is an overreaction to sector-wide FUD or a fundamental repricing. Investors are bracing for tonight's earnings report, with high options volatility signaling uncertainty as they weigh the company's role in powering AI data centers against mounting debt concerns and recent negative short-seller sentiment.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing intense volatility and downward pressure as investors weigh strong earnings fundamentals against concerns over the broader memory chip cycle and intensifying competition from Chinese manufacturers. The stock remains a focal point for community debate, with bulls citing robust AI-driven demand and attractive valuation multiples, while bears emphasize technical breakdowns and the potential for a deeper cyclical correction.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the stock's significant decline presents a deep-value opportunity ahead of an upcoming restructuring plan and earnings report. The community is actively discussing the potential impact of a global cost-cutting program aimed at reinvesting for long-term growth, while also weighing heavy institutional interest and options activity against broader sector rotation out of volatile tech.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is under intense scrutiny following earnings results and a significant downward revision to its 2026 GAAP EPS guidance, compounded by broader industry pressure from the Trump administration's plan to end Medicare Part D drug subsidies. The community is actively debating the stock's future amid these regulatory headwinds, with some investors focusing on Humana's heavy Medicare Advantage concentration while others compare its valuation and operational stability against competitors like UnitedHealth.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors debate whether the recent sharp sell-off is a manipulative algorithmic trap or a fundamental correction following broader semiconductor sector volatility. Community discussion is sharply divided between retail investors bracing for further downside and bulls pointing to long-term foundry execution and AI-driven growth catalysts as reasons to buy the dip.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate Technology is trending following a significant fiscal Q4 earnings beat and strong forward-looking guidance, which sparked a sector-wide rebound after investors were rattled by broader semiconductor weakness. The community is actively debating whether this performance confirms a multi-year bull run for AI-driven storage demand or if the stock is merely caught in a volatile cycle of institutional rotation.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is seeing increased trading interest following a Q2 earnings beat and a significant upward revision to its full-year profit and free cash flow guidance. The community is actively discussing the company's momentum in its gas and hybrid segments, while simultaneously weighing the impact of ongoing EV-related charges against the automaker's long-term profitability strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?

Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 PR Newswire DUBLIN, July 20, 2026 DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will...

Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.

Axsome Begins Phase III Study on Solriamfetol for ADHD in Children

AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$256.92
Prev Close	$255.43
Open	$259.73
Dividend Yield	0.00%
50-Day Moving Average	$238.04
Beta	0.70
Avg. Volume	942,401.41
PE Ratio	-13,963.04

52-Week High	$261.30
52-Week Low	$105.00
Market Capitalization	$16.05B
EPS (Annual)	-$5.84
Price to Book	3.55
Revenue Per Employee	$1.48M

Feed

News

Sentiment

Earnings

Fundamentals

Info

JAZZJazz Pharmaceuticals plc

Latest JAZZ News